Evidence map›Paper›PMID 28710429›Full record

ArticleScientific reports2017

The A2V mutation as a new tool for hindering Aβ aggregation: A neutron and x-ray diffraction study.

Laura Cantu', Laura Colombo, Tatiana Stoilova, Bruno Demé, Hideyo Inouye, Rachel Booth, Valeria Rondelli, Giuseppe Di Fede, Fabrizio Tagliavini, Elena Del Favero and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Aβ1-6Molecular psychiatry · 2023
    Article
  4. Review
  5. Article
  6. Halogenation of theChemistryOpen · 2020
    Article
  7. Review
  8. Translational Research in Alzheimer's and Prion Diseases.Journal of Alzheimer's disease : JAD · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Laura Cantu'Department of Medical Biotechnology and Translational Medicine, University of Milan, LITA, Segrate, 20090, Milano, Italy.
Laura ColomboDepartment of Molecular Biochemistry and Pharmacology, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milano, 20156, Italy.
Tatiana StoilovaDepartment of Molecular Biochemistry and Pharmacology, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milano, 20156, Italy.
Bruno DeméInstitut Laue-Langevin, Grenoble, Cedex 9, 38042, France.
Hideyo InouyeDepartment of Electrical and Computer Engineering, Northeastern University College of Engineering, Boston, MA, 02115, USA.
Rachel BoothBiology Department, Boston College, Chestnut Hill, MA, 02467-3811, USA.
Valeria RondelliDepartment of Medical Biotechnology and Translational Medicine, University of Milan, LITA, Segrate, 20090, Milano, Italy.
Giuseppe Di FedeNeurology V and Neuropathology Unit, IRCCS Foundation "Carlo Besta" Neurological Institute (INCB), Milano, 20133, Italy.
Fabrizio TagliaviniNeurology V and Neuropathology Unit, IRCCS Foundation "Carlo Besta" Neurological Institute (INCB), Milano, 20133, Italy.
Elena Del FaveroDepartment of Medical Biotechnology and Translational Medicine, University of Milan, LITA, Segrate, 20090, Milano, Italy.
Daniel A KirschnerBiology Department, Boston College, Chestnut Hill, MA, 02467-3811, USA.
Mario SalmonaDepartment of Molecular Biochemistry and Pharmacology, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milano, 20156, Italy. mario.salmona@marionegri.it.
University of Milan · ITBoston College · USFondazione IRCCS Istituto Neurologico Carlo Besta · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITInstitut Laue-Langevin · FRMario Negri Institute for Pharmacological Research · ITNortheastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have described a novel C-to-T mutation in the APP gene that corresponds to an alanine to valine substitution at position 673 in APP (A673V), or position 2 of the amyloid-β (Aβ) sequence. This mutation is associated with the early onset of AD-type dementia in homozygous individuals, whereas it has a protective effect in the heterozygous state. Correspondingly, we observed differences in the aggregation properties of the wild-type and mutated Aβ peptides and their mixture. We have carried out neutron diffraction (ND) and x-ray diffraction (XRD) experiments on magnetically-oriented fibers of Aβ1-28WT and its variant Aβ1-28A2V. The orientation propensity was higher for Aβ1-28A2V suggesting that it promotes the formation of fibrillar assemblies. The diffraction patterns by Aβ1-28WT and Aβ1-28A2V assemblies differed in shape and position of the equatorial reflections, suggesting that the two peptides adopt distinct lateral packing of the diffracting units. The diffraction patterns from a mixture of the two peptides differed from those of the single components, indicating the presence of structural interference during assembly and orientation. The lowest orientation propensity was observed for a mixture of Aβ1-28WT and a short N-terminal fragment, Aβ1-6A2V, which supports a role of Aβ's N-terminal domain in amyloid fibril formation.

Indexed as

Amino Acid SubstitutionAmyloid beta-PeptidesAmyloid beta-Protein PrecursorHumansNeutron DiffractionProtein DomainsX-Ray DiffractionAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, human

Identifiers

PMID28710429
PMCPMC5511251
OpenAlexW2736193755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.